/R E P E A T -- Media Advisory - Canada, Government of Nunavut, and Nunavut Tunngavik Inc. to sign a Joint Declaration of Intent on construction of treatment facility/
IQALUIT, Aug. 16, 2019 /CNW/ - Please be advised that the Honourable Seamus O'Regan, Minister of Indigenous Services, alongside the Honourable David Joanasie, Government of Nunavut Minister of Culture and Heritage, and President Aluki Kotierk, Nunavut Tunngavik Inc. will sign a joint declaration of intent on the path forward for the construction of a treatment facility in Nunavut.
Minister O'Regan will be available to the media following the signing.
Date: Monday, August 19, 2019 Time: 1:30PM (EDT)
Where: Frobisher Inn Koojesse Room Astro Hill Complex Iqaluit NU X0A 0H0
Medtronic plc , a global leader in healthcare technology, today announced that the U.S. Food and Drug Administration (FDA) has approved the Inceptivtm closed-loop rechargeable spinal cord stimulator (SCS) for the treatment of chronic pain. Inceptiv...
The "KEYTRUDA Market Size, Forecast, and Emerging Insight - 2032" report has been added to ResearchAndMarkets.com's offering.
The report provides comprehensive insights about KEYTRUDA for ovarian cancer in the seven major markets. A detailed...
The "Peptide Synthesis Market: Industry Trends and Global Forecasts, Till 2035: Distribution by Type of Peptide Synthesis Method, Type of Chemical Synthesis, Contract Manufacturing Organization Size, Key Geographical Regions" report has been added to...
The "Laboratory Filtration Equipment - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.
Global Laboratory Filtration Equipment Market to Reach $3 Billion by 2030
The global market for Laboratory...
The "Global Weight Loss Drugs Market: Analysis By Product Type, By Drug Type, By Distribution Channel, By End User, By Region, Size and Trends with Impact of COVID-19 and Forecast up to 2029" report has been added to ResearchAndMarkets.com's...
Arrowhead Pharmaceuticals, Inc. today announced its plan to host a 2024 Summer Series of R&D webinars that highlight multiple clinical stage RNA interference (RNAi) based medicines that utilize the company's proprietary Targeted RNAi Molecule...
